S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
NASDAQ:OPK

OPKO Health (OPK) Stock Price, News & Analysis

$0.95
-0.02 (-2.07%)
(As of 02/23/2024 ET)
Today's Range
$0.94
$1.00
50-Day Range
$0.89
$1.62
52-Week Range
$0.85
$2.24
Volume
6.49 million shs
Average Volume
7.17 million shs
Market Capitalization
$731.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.85

OPKO Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
307.0% Upside
$3.85 Price Target
Short Interest
Bearish
23.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.28mentions of OPKO Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$6.55 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.25) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.47 out of 5 stars

Medical Sector

99th out of 942 stocks

Pharmaceutical Preparations Industry

33rd out of 428 stocks


OPK stock logo

About OPKO Health Stock (NASDAQ:OPK)

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Stock Price History

OPK Stock News Headlines

OPKO Health (OPK) Set to Announce Earnings on Tuesday
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
OPKO Health (NASDAQ:OPK) Lowered to Sell at StockNews.com
Opko Health Inc
Opko Health Board Member Alexis Borisy to Depart
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Opko Health
3 Stocks with Major Insider Buying This Month
OPK Dec 2024 1.000 put
OPK Dec 2024 3.000 put
Why OPKO Health Stock Is Getting Hammered
See More Headlines
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/24/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
4,196
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.85
High Stock Price Target
$5.40
Low Stock Price Target
$2.00
Potential Upside/Downside
+307.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-328,400,000.00
Pretax Margin
-24.68%

Debt

Sales & Book Value

Annual Sales
$1.00 billion
Book Value
$2.02 per share

Miscellaneous

Free Float
443,580,000
Market Cap
$731.31 million
Optionable
Optionable
Beta
1.78
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Phillip Frost Ph.D. (Age 88)
    Chairman & CEO
    Comp: $972.2k
  • Dr. Jane H. Hsiao M.B.A. (Age 77)
    Ph.D., Vice Chairman & Chief Technical Officer
    Comp: $912.2k
  • Dr. Elias Adam Zerhouni M.D. (Age 73)
    President & Vice Chairman
    Comp: $1.41M
  • Mr. Adam E. Logal (Age 46)
    Senior VP, CFO, Chief Accounting Officer & Treasurer
    Comp: $712.2k
  • Mr. Steven D. Rubin Esq. (Age 64)
    J.D., Executive VP of Administration & Director
    Comp: $822.2k
  • Dr. Akhtar Ashfaq
    Senior Vice President of Clinical Research & Development and Medical Affairs
  • Dr. Gary J. Nabel M.D. (Age 69)
    Ph.D., Chief Innovation Officer & Director
  • Dr. David Okrongly Ph.D. (Age 65)
    President of OPKO Diagnostics
  • Dr. Charles W. Bishop (Age 72)
    Chief Executive Officer of OPKO Renal
  • Dr. Antonio F. Cruz (Age 71)
    President of Transition Therapeutics














OPK Stock Analysis - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings
or view top-rated stocks.

What is OPKO Health's stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for OPKO Health's stock. Their OPK share price targets range from $2.00 to $5.40. On average, they expect the company's share price to reach $3.85 in the next twelve months. This suggests a possible upside of 307.0% from the stock's current price.
View analysts price targets for OPK
or view top-rated stocks among Wall Street analysts.

How have OPK shares performed in 2024?

OPKO Health's stock was trading at $1.51 at the beginning of the year. Since then, OPK shares have decreased by 37.4% and is now trading at $0.9460.
View the best growth stocks for 2024 here
.

When is OPKO Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our OPK earnings forecast
.

How can I listen to OPKO Health's earnings call?

OPKO Health will be holding an earnings conference call on Tuesday, February 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "6034226".

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) announced its earnings results on Monday, November, 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company had revenue of $178.60 million for the quarter, compared to analyst estimates of $174.78 million. OPKO Health had a negative trailing twelve-month return on equity of 13.63% and a negative net margin of 23.94%. The business's revenue was down .6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) earnings per share.

What ETFs hold OPKO Health's stock?
What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.14%), Charles Schwab Investment Management Inc. (0.74%), Northern Trust Corp (0.65%), Dimensional Fund Advisors LP (0.45%), Goldman Sachs Group Inc. (0.38%) and Norges Bank (0.35%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jane Ph D Hsiao, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Richard M Krasno, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPK) was last updated on 2/25/2024 by MarketBeat.com Staff